eligibility_summary
Inclusion: Adults 18–80 with pathology‑confirmed CRC and unresectable, liver‑dominant mets after 1st/2nd‑line failure, measurable (mRECIST), ECOG 0–1, Child‑Pugh A/B≤7, ≥3‑mo survival, adequate organ function, consent. Exclusion: extensive extrahepatic disease, HER2 3+/amp or MSI‑H/dMMR, contrast/oxaliplatin/cetuximab allergy, pregnancy, active infection, recent severe GI bleed, heart disease/MI, severe organ disease or uncontrolled diabetes.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: ctDNA-guided combination of hepatic arterial infusion chemotherapy (HAIC), tislelizumab, and either cetuximab rechallenge or fruquintinib for MSS colorectal cancer liver metastases after standard therapy failure. Drug types/mechanisms: HAIC with oxaliplatin (platinum DNA crosslinker), irinotecan (topoisomerase I inhibitor), and 5-fluorouracil (antimetabolite, thymidylate synthase blockade), liver-directed delivery, with optional drug-eluting TACE for hypervascular lesions. Tislelizumab: anti-PD-1 monoclonal antibody restoring cytotoxic T-cell activity. Cetuximab: anti-EGFR mAb (rechallenge in RAS/NRAS/BRAF/EGFR wild-type), blocking EGFR→RAS/RAF/MEK/ERK. Fruquintinib: small-molecule VEGFR1-3 TKI, anti-angiogenic, normalizes TME to enhance PD-1 response. Targets/pathways: PD-1 on T cells, EGFR-MAPK in tumor cells, VEGF/VEGFR on endothelial cells, DNA replication/repair and Topo-I in tumor cells, liver-focused delivery to hepatic metastases.